CAS 221231-10-3 AOD-9604 2mg/vial Human Growth Hormone Peptide

CAS 221231-10-3 AOD-9604 2mg/vial Human Growth Hormone Peptide

Nom du produit: AOD 9604

Synonymes: AOD 9604

CAS:221231-10-3

MF : C78H123N23O23S2

Pureté : 98%

Classe : Qualité pharmaceutique

Espace de rangement: Fermé, dessous 2 ~ 8°C preservation

Usage : AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area,increase in muscle mass, et améliore la teneur en lipides du corps.

MOQ:10vial

Prix:negotiation according your quantity

Emballage:Hundreds of Discreet Packing and we could offer special packing only for you.

Payment Way:Gramme d'argent;Western union; Bitcoin; virement.

Delivery time: 3-6 jours de travail

Shipping Courier: HKEMS, DHL;UPS, Fedex, TNT

Our market:all over the world

The Fat Loss Properties of AOD 9604
Dans des tests en laboratoire sur des cellules graisseuses de rongeurs, les cochons, chiens, et les humains, the H fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, amélioré la combustion des graisses. Chez les rongeurs (rats et souris), H fragment reduced body fat in obese animals but, combustion améliorée des graisses sans modifier la consommation alimentaire ni induire la croissance (as it does not increase IGF levels) or any other unwanted G H effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, et améliore la teneur en lipides du corps.
These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 et 178-191. en outre, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Aussi, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).

AOD9604 – What is it?

AOD9604 is a peptide (a chain of amino acids) which was developed and patented by a company called Metabolic Pharmaceuticals in Australia in the late 1990s. AOD stands for “Anti Obesity Drug”. This peptide has an amino acid sequence that mimics the lipolytic region of human G H (the region of this hormone thought to be responsible for burning fat) and it has been promoted variously as a weight loss supplement, as an aid to muscle and cartilage repair, and a treatment for osteoarthritis by its manufacturers. It is also known as lipotropin and Tyr-H fragment, and is generally available these days as a transdermal cream or an injectable.

Growth Hormone Peptides